Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 50.65M P/E - EPS this Y -2.30% Ern Qtrly Grth -
Income -31.08M Forward P/E -1.54 EPS next Y 8.00% 50D Avg Chg -22.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 1.42 EPS next 5Y - 52W High Chg -72.00%
Recommedations 2.00 Quick Ratio 2.90 Shares Outstanding 40.13M 52W Low Chg 62.00%
Insider Own 0.56% ROA -93.70% Shares Float 33.94M Beta 1.40
Inst Own 28.20% ROE -108.31% Shares Shorted/Prior 709.88K/647.49K Price 1.73
Gross Margin - Profit Margin - Avg. Volume 167,724 Target Price 6.20
Oper. Margin - Earnings Date Aug 8 Volume 29,537 Change 2.98%
About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics, Inc. News
11/15/24 Life Sciences Investor Forum: Presentations Now Available for Online Viewing
11/13/24 Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
11/12/24 Life Sciences Investor Forum Agenda Announced for November 14th
11/12/24 Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
10/31/24 Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
10/29/24 Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
10/23/24 Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
10/22/24 Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
10/09/24 Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...
10/02/24 Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
10/01/24 Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
09/03/24 Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
08/22/24 Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
08/08/24 Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
08/05/24 Cognition Therapeutics to Report Second Quarter 2024 Financial Results
07/30/24 Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
07/29/24 Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
07/26/24 Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
07/02/24 Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
06/24/24 Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
CGTX Chatroom

User Image WeAllFallDown Posted - 2 minutes from now

$CGTX Lisa knows what she has and will be first to bring to the market, a total game changer for all of us! LBD is devastating so any treatment is better than nothing...

User Image Ataifanboymentalhealthz Posted - 55 minutes ago

@Foramen_canal @DLBEE $CGTX can use atm without sec filing immediately being done. They don’t report it until earnings good example would be $TPST

User Image Foramen_canal Posted - 8 hours ago

$CGTX

User Image DLBEE Posted - 12 hours ago

$CGTX Outstanding stock rising from 40.13 million to 41.5 million Lisa is using offering again carefully.

User Image Ataifanboymentalhealthz Posted - 12 hours ago

@jiggs10 that’s the gamble with biotech $CGTX if results good that may not be bad price target problem is if trial fails going to .15 cents fast. Therefore manage your risk accordingly

User Image jiggs10 Posted - 14 hours ago

$CGTX People will be Elaytad if it works.

User Image Foramen_canal Posted - 16 hours ago

$CGTX Beware with fake long and soft bashers .

User Image jiggs10 Posted - 16 hours ago

$CGTX Stock will be good for a tax loss at end of year with many selling

User Image Poortfolio Posted - 17 hours ago

$CGTX $CGTX wf would not let me put $.445 in so I did $.45 now I can’t buy more at $.45 😭

User Image Foramen_canal Posted - 19 hours ago

$CGTX DLB MARKET GOING TO BE 8.45 billion . LISA SAID THEY WILL BE THE FIRST TO LAUNCH DLB TREATMENT ANY MINIATURE IMPROVEMENT WILL HELP THIS HORRIBLE DISEASE . Collaboration or Buyout imminent with little improvement in DLB.https://finance.yahoo.com/news/lewy-body-dementia-treatment-market-120000536.html

User Image trekker314 Posted - 19 hours ago

$CGTX Shimmer Phase 2 due soon. Anyone know when Phase 3 FDA meeting is supposed to happen for Shine? " We look forward to discussing these results and potential approaches to Phase 3 with the FDA in an end-of-Phase 2 meeting,” concluded Dr. Caggiano."

User Image Stbullll Posted - 19 hours ago

$CGTX with $ 220k volume on first hour What is happening? Shorts covering?

User Image WeAllFallDown Posted - 1 day ago

$CGTX Grabbing more shares tomorrow before the results are reported and or a possible collaboration announcement

User Image WeAllFallDown Posted - 1 day ago

$CGTX CT1812 appears to be the real deal with additional data due out before end of the year...just watched the investor conference video...interesting findings

User Image MayoMobile Posted - 1 day ago

$CGTX If this goes much lower I may need to double down.

User Image WeAllFallDown Posted - 1 day ago

$CGTX Just watched the company produced Shimmer Study video, so data dump by end of year? If it demonstrates strong enough signals then we push onto Phase 3? Currently no marketable treatments in existence...incredible yet sad...what an opportunity!

User Image Appa1942 Posted - 1 day ago

$CGTX none that I have herd of

User Image WeAllFallDown Posted - 1 day ago

$CGTX Is there any solution on currently on the market to slow or treat effects of LBD? Do they have something marketable in the near future or strong data?

User Image Max62954 Posted - 1 day ago

$CGTX pretty dead board here hopefully I found a good one

User Image Stbullll Posted - 1 day ago

$CGTX Still holding Not selling a single share

User Image Foramen_canal Posted - 1 day ago

$CGTX DLB RESULTS ARE FEW WEEKS AWAY THEY ARE STEALING CHEAP . BUY EVERY DIP !

User Image Foramen_canal Posted - 2 days ago

$CGTX loading zone

User Image jiggs10 Posted - 2 days ago

$CGTX .47 cents to $11. Someone is smoking crack.

User Image Stbullll Posted - 3 days ago

$CGTX https://www.webull.com/news/11796695050765312

User Image Thestocktraderhubzee Posted - 3 days ago

WATCHLIST NOV 18 2024 $CGTX Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target $VNRX D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target $HQI Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18 $KYTX Wells Fargo Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $24 $CNTA Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $28

User Image DLBEE Posted - 5 days ago

$CGTX is this a reason for todays drop? https://finance.yahoo.com/news/biogen-partner-eisai-gets-positive-140400531.html

User Image Foramen_canal Posted - 5 days ago

$CGTX Thinking about to pawn my some old stuff to add more . Need more dry powder to add .

User Image MayoMobile Posted - 5 days ago

$CGTX Alzheimers overview: https://www.sotcanalytics.com/cognition-therapeutics-cgtx $CGTX CTAD 2024 commentary: https://www.sotcanalytics.com/ctad-2024#h.rphjzz4qv9ki

User Image MayoMobile Posted - 5 days ago

$CGTX just increased my starter position by 63%. SHIMMER phase 2 LBD topline expected by EoY.

Analyst Ratings
HC Wainwright & Co. Buy Aug 12, 24
B. Riley Securities Neutral Aug 6, 24
HC Wainwright & Co. Buy Aug 1, 24
Cantor Fitzgerald Neutral Jul 30, 24
Rodman & Renshaw Buy Jul 2, 24
Chardan Capital Buy Jun 6, 24
HC Wainwright & Co. Buy May 29, 24
B. Riley Securities Buy Mar 28, 24
Oppenheimer Outperform Mar 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fletcher Aaron G.L. Director Director Nov 28 Buy 2.65 16,064 42,570 309,748 11/29/22
Kreis Leslie W. Director Director Nov 28 Buy 2.65 16,064 42,570 309,748 11/29/22
Fletcher Aaron G.L. Director Director Nov 16 Buy 1.4 71,000 99,400 307,877 11/17/22
Kreis Leslie W. Director Director Nov 16 Buy 1.4 71,000 99,400 307,877 11/17/22
Fletcher Aaron G.L. Director Director Nov 15 Buy 1.2 1,500,000 1,800,000 299,608 11/16/22
Kreis Leslie W. Director Director Nov 15 Buy 1.2 1,500,000 1,800,000 299,608 11/16/22
BIOS Memory SPV I, LP 10% Owner 10% Owner Oct 13 Buy 12 190,000 2,280,000 899,905 10/15/21
BIOS Memory SPV I, LP 10% Owner 10% Owner Oct 13 Sell 12 90 1,083 385,248 10/15/21
Fletcher Aaron G.L. Director Director Oct 13 Buy 12 190,000 2,280,000 899,905 10/15/21
Fletcher Aaron G.L. Director Director Oct 13 Sell 12 90 1,083 385,248 10/15/21
Golden Seeds Cognition Therape... 10% Owner 10% Owner Oct 13 Sell 12 33 397 2,177,985 10/15/21
Ogden CAP Associates, LLC 10% Owner 10% Owner Oct 13 Sell 12 74 889 2,210,377 10/15/21
Breedlove Mark H. Director Director Oct 13 Sell 12 12 141 404,439 10/15/21